1
|
Dandapath I, Das S, Charan BD, Garg A, Suri A, Kedia S, Sharma MC, Sarkar C, Khonglah Y, Ahmed S, Suri V. Evaluation of KIAA1549::BRAF fusions and clinicopathological insights of pilocytic astrocytomas. Ann Diagn Pathol 2024; 72:152318. [PMID: 38733671 DOI: 10.1016/j.anndiagpath.2024.152318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2024] [Revised: 04/07/2024] [Accepted: 04/15/2024] [Indexed: 05/13/2024]
Abstract
BACKGROUND Pilocytic astrocytoma (PAs) represents a significant portion of childhood primary brain tumors, with distinct histological and radiological features. The prevalence of KIAA1549::BRAF fusion in PAs has been well-established, this study aims to assess the prevalence of KIAA1549::BRAF fusions and explore their associations with tumor characteristics, radiological findings, and patient outcomes in PAs. METHODS Histologically confirmed cases of PAs from a 5-year period were included in the study. Demographic, histopathological, and radiological data were collected, and immunohistochemistry was performed to characterize tumor markers. FISH and qRT-PCR assays were employed to detect KIAA1549::BRAF fusions. Statistical analyses were conducted to examine associations between fusion status and various other parameters. RESULTS Histological analysis revealed no significant differences in tumor features based on fusion status. However, younger age groups showed higher fusion prevalence. Radiologically, fusion-positive cases were distributed across different tumor subtypes SE, CWE and NCWE. Survival analysis did not demonstrate a significant impact of fusion status on overall survival, however most cases with recurrence and death harboured KIAA1549::BRAF fusion. Of 200 PAs, KIAA1549::BRAF fusions were detected in 64 % and 74 % of cases via qRT-PCR and FISH, respectively. Concordance between the two platforms was substantial (86 %). CONCLUSION KIAA1549::BRAF fusions are prevalent in PAs and can be reliably detected using both FISH and qRT-PCR assays. Cost considerations suggest qRT-PCR as a more economical option for fusion detection in routine clinical practice.
Collapse
Affiliation(s)
- Iman Dandapath
- Neuropathology Laboratory, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India
| | - Sumanta Das
- Neuropathology Laboratory, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India
| | - Bheru Dan Charan
- Department of Neuroradiology, All, India Institute of Medical Science, New Delhi, India
| | - Ajay Garg
- Department of Neuroradiology, All, India Institute of Medical Science, New Delhi, India
| | - Ashish Suri
- Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
| | - Shweta Kedia
- Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
| | - Mehar Chand Sharma
- Neuropathology Laboratory, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India
| | - Chitra Sarkar
- Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
| | - Yookarin Khonglah
- Department of Pathology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India
| | - Shabnam Ahmed
- Department of Pathology, GNRC Hospitals, Dispur, Assam, India
| | - Vaishali Suri
- Neuropathology Laboratory, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India.
| |
Collapse
|
2
|
Balinda HU, Sedgwick A, D'Souza-Schorey C. Mechanisms underlying melanoma invasion as a consequence of MLK3 loss. Exp Cell Res 2022; 415:113106. [DOI: 10.1016/j.yexcr.2022.113106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 03/09/2022] [Accepted: 03/10/2022] [Indexed: 11/27/2022]
|
3
|
González-Antonio O, Navarro Villalobos M, Vázquez-Alvarado MM, Santillan R, Flores-Pérez B, Romero-Ávila M, Farfán N. On the nucleophilic derivatization of 4,7-dibromo-[1,2,5]thiadiazolo[3,4- c]pyridine: basis for biologically interesting species and building blocks for organic materials. NEW J CHEM 2019. [DOI: 10.1039/c9nj01855g] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Eleven new thiadiazolopyridine-derived building blocks were synthesized through a selective SNAr reaction and the key steps of their reaction mechanism and spectroscopic properties were studied.
Collapse
Affiliation(s)
- Oscar González-Antonio
- Facultad de Química
- Departamento de Química Orgánica
- Universidad Nacional Autónoma de México
- Ciudad Universitaria
- 04510 Ciudad de México
| | | | - María Magdalena Vázquez-Alvarado
- Facultad de Química
- Departamento de Química Orgánica
- Universidad Nacional Autónoma de México
- Ciudad Universitaria
- 04510 Ciudad de México
| | - Rosa Santillan
- Departamento de Química
- Centro de Investigación y de Estudios Avanzados del IPN
- CINVESTAV
- 07000 Ciudad de México
- Mexico
| | - Blas Flores-Pérez
- Facultad de Química
- Departamento de Química Orgánica
- Universidad Nacional Autónoma de México
- Ciudad Universitaria
- 04510 Ciudad de México
| | - Margarita Romero-Ávila
- Facultad de Química
- Departamento de Química Orgánica
- Universidad Nacional Autónoma de México
- Ciudad Universitaria
- 04510 Ciudad de México
| | - Norberto Farfán
- Facultad de Química
- Departamento de Química Orgánica
- Universidad Nacional Autónoma de México
- Ciudad Universitaria
- 04510 Ciudad de México
| |
Collapse
|
4
|
Ryall S, Arnoldo A, Krishnatry R, Mistry M, Khor K, Sheth J, Ling C, Leung S, Zapotocky M, Guerreiro Stucklin A, Lassaletta A, Shago M, Tabori U, Hawkins CE. Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System. J Neuropathol Exp Neurol 2017; 76:562-570. [DOI: 10.1093/jnen/nlx042] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Amin KM, El-Badry OM, Rahman DEA, Ammar UM, Abdalla MM. Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone. ACTA ACUST UNITED AC 2016. [DOI: 10.5155/eurjchem.7.1.19-29.1346] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
6
|
Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BMJM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 2015; 27:85-96. [PMID: 25500121 PMCID: PMC4297292 DOI: 10.1016/j.ccell.2014.11.006] [Citation(s) in RCA: 154] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2014] [Revised: 08/11/2014] [Accepted: 11/07/2014] [Indexed: 01/07/2023]
Abstract
BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which drive paradoxical reactivation of the pathway. We describe pan-RAF inhibitors (CCT196969, CCT241161) that also inhibit SFKs. These compounds do not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma. They inhibit melanoma cells and patient-derived xenografts that are resistant to BRAF and BRAF/MEK inhibitors. Thus, paradox-breaking pan-RAF inhibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistance.
Collapse
Affiliation(s)
- Maria Romina Girotti
- Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Filipa Lopes
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Natasha Preece
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Dan Niculescu-Duvaz
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Alfonso Zambon
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Lawrence Davies
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Steven Whittaker
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Grazia Saturno
- Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Amaya Viros
- Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Malin Pedersen
- Targeted Therapy Team, The Institute of Cancer Research, London SW3 6JB, UK
| | - Bart M J M Suijkerbuijk
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Delphine Menard
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Robert McLeary
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Louise Johnson
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Laura Fish
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK
| | - Sarah Ejiama
- Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Berta Sanchez-Laorden
- Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Juliane Hohloch
- Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Neil Carragher
- Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK
| | - Kenneth Macleod
- Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK
| | - Garry Ashton
- Histology Unit, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Anna A Marusiak
- Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Alberto Fusi
- University of Manchester, Christie NHS Foundation Trust, Manchester M20 4BX, UK
| | - John Brognard
- Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK
| | - Margaret Frame
- Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK
| | - Paul Lorigan
- University of Manchester, Christie NHS Foundation Trust, Manchester M20 4BX, UK
| | - Richard Marais
- Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX, UK.
| | - Caroline Springer
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
| |
Collapse
|
7
|
El-Nassan HB. Recent progress in the identification of BRAF inhibitors as anti-cancer agents. Eur J Med Chem 2014; 72:170-205. [DOI: 10.1016/j.ejmech.2013.11.018] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2013] [Revised: 11/05/2013] [Accepted: 11/18/2013] [Indexed: 12/26/2022]
|
8
|
Abstract
Activating BRAF mutations, leading to constitutive activation of the MAPK signaling pathway, are common in a variety of human cancers. Several small molecule BRAF inhibitors have been developed during the last years and shown promising results in clinical trials, especially for metastatic melanoma, while they have been less effective in colon cancer. Two inhibitors, vemurafenib and dabrafenib, have been approved for treatment of melanoma. Unfortunately, in most patients who initially respond the tumors eventually develop acquired resistance to the BRAF inhibitors. So far, a number of resistance mechanisms have been identified, including secondary NRAS mutations and BRAF alternative splicing, leading to reactivation of the MAPK pathway. Other alterations, both upstream and downstream of BRAF can have the same effect, and activation of alternative pathways can also play a role in resistance to BRAF inhibitors. In addition, intra-tumor heterogeneity with the presence of clones of tumor cells lacking BRAF mutations needs to be considered, since wildtype BRAF can be activated by inhibitors designed to target mutated BRAF. Combination of the BRAF inhibitor dabrafenib with the MEK inhibitor trametinib has significantly prolonged progression free survival compared to dabrafenib alone in metastatic melanoma. Combination treatments of BRAF inhibitors with other agents may not only circumvent or delay resistance, but may also lead to fewer side effects, such as development of secondary squamous tumors. Several clinical trials are underway for many different BRAF mutation positive cancers with BRAF inhibitors alone or in combination with other small molecule inhibitors, immunotherapies or conventional chemotherapy.
Collapse
|
9
|
Falck Miniotis M, Arunan V, Eykyn TR, Marais R, Workman P, Leach MO, Beloueche-Babari M. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. Cancer Res 2013; 73:4039-49. [PMID: 23639941 DOI: 10.1158/0008-5472.can-12-1969] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The RAS/BRAF/MEK/ERK signaling pathway is a central driver in cancer with many BRAF and MEK inhibitors being evaluated in clinical trials. Identifying noninvasive biomarkers of early pharmacodynamic responses is important for development of these targeted drugs. As increased aerobic glycolysis is often observed in cancer, we hypothesized that MEK1/2 (MAP2K1/MAP2K2) inhibitors may reduce lactate levels as detected by magnetic resonance spectroscopy (MRS), as a metabolic biomarker for the pharmacodynamic response. MRS was used to monitor intracellular and extracellular levels of lactate in human cancer cells in vitro and in melanoma tumors ex vivo. In addition, we used (1)H MRS and a fluorescent glucose analog to evaluate the effect of MEK inhibition on glucose uptake. MEK1/2 signaling inhibition reduced extracellular lactate levels in BRAF-dependent cells but not BRAF-independent cells. The reduction in extracellular lactate in BRAF-driven melanoma cells was time-dependent and associated with reduced expression of hexokinase-II driven by c-Myc depletion. Taken together, these results reveal how MEK1/2 inhibition affects cancer cell metabolism in the context of BRAF oncogene addiction. Furthermore, they offer a preclinical proof-of-concept for the use of MRS to measure lactate as a noninvasive metabolic biomarker for pharmacodynamic response to MEK1/2 inhibition in BRAF-driven cancers.
Collapse
Affiliation(s)
- Maria Falck Miniotis
- Cancer Research UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
10
|
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2013; 3:1068-111. [PMID: 23085539 PMCID: PMC3717945 DOI: 10.18632/oncotarget.659] [Citation(s) in RCA: 256] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Targeting these pathways is often complex and can result in pathway activation depending on the presence of upstream mutations (e.g., Raf inhibitors induce Raf activation in cells with wild type (WT) RAF in the presence of mutant, activated RAS) and rapamycin can induce Akt activation. Targeting with inhibitors directed at two constituents of the same pathway or two different signaling pathways may be a more effective approach. This review will first evaluate potential uses of Raf, MEK, PI3K, Akt and mTOR inhibitors that have been investigated in pre-clinical and clinical investigations and then discuss how cancers can become insensitive to various inhibitors and potential strategies to overcome this resistance.
Collapse
Affiliation(s)
- James A McCubrey
- Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Auphan-Anezin N, Verdeil G, Grange M, Soudja SM, Wehbe M, Buferne M, Mas A, Schmitt-Verhulst AM. Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells? Pigment Cell Melanoma Res 2012; 26:167-75. [PMID: 23217139 DOI: 10.1111/pcmr.12056] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2012] [Accepted: 11/28/2012] [Indexed: 01/05/2023]
Abstract
Discovery of tumor antigen (TA) recognized by autologous T cells (TCs) in patients with melanoma has led to clinical protocols using either vaccination or adoptive transfer of TA-specific TCs. However, efficacy of these treatments has been hampered by inhibitory effects exerted on tumor-infiltrating TCs by tumor-intrinsic mediators or by recruitment of immunosuppressive cells. A mouse model of autochthonous melanoma recapitulates some aspects of inflammatory melanoma development in patients. These include a systemic Th2-/Th17-oriented chronic inflammation, recruitment of immunosuppressive myeloid cells and acquisition by tumor-infiltrating TCs of an 'exhausted' phenotype characterized by expression of multiple inhibitory receptors including programmed death-1, also expressed on patients' melanoma-infiltrating TCs. Rather than using extracellular blocking reagents to inhibitory surface molecules on TCs, we sought to dampen negative signaling exerted on them. Adoptively transferred TCs presenting increased cytokine receptor signaling due to expression of an active Stat5 transcription factor were efficient at inducing melanoma regression in the preclinical melanoma model. These transferred TCs thrived and retained expression of effector molecules in the melanoma microenvironment, defining a protocol endowing TCs with the ability to resist melanoma-induced immunosuppression.
Collapse
Affiliation(s)
- Nathalie Auphan-Anezin
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille Université UM2, Marseille, France.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Cho KJ, Kasai RS, Park JH, Chigurupati S, Heidorn SJ, van der Hoeven D, Plowman SJ, Kusumi A, Marais R, Hancock JF. Raf inhibitors target ras spatiotemporal dynamics. Curr Biol 2012; 22:945-55. [PMID: 22560614 DOI: 10.1016/j.cub.2012.03.067] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2011] [Revised: 02/10/2012] [Accepted: 03/20/2012] [Indexed: 12/19/2022]
Abstract
BACKGROUND The lateral segregation of Ras proteins into transient plasma membrane nanoclusters is essential for high-fidelity signal transmission by the Ras mitogen-activated protein kinase (MAPK) cascade. In this spatially constrained signaling system, the dynamics of Ras nanocluster assembly and disassembly control MAPK signal output. RESULTS We show here that BRaf inhibitors paradoxically activate CRaf and MAPK signaling in Ras transformed cells by profoundly dysregulating Ras nanocluster dynamics. Specifically, BRaf inhibitors selectively enhance the plasma membrane nanoclustering of oncogenic K-Ras and N-Ras but have no effect on H-Ras nanoclustering. Raf inhibitors are known to drive the formation of stable BRaf-CRaf and CRaf-CRaf dimers. Our results demonstrate that the presence of two Ras-binding domains in a single Raf dimer is sufficient and required to increase Ras nanoclustering, indicating that Raf dimers promote K- and N-Ras nanocluster formation by crosslinking constituent Ras proteins. Ras crosslinking increases the fraction of K-Ras and N-Ras in their cognate nanoclusters, leading to an increase in MAPK output from the plasma membrane. Intriguingly, increased MAPK signaling in BRaf inhibited cells is accompanied by significantly decreased Akt activation. We show that this signal pathway crosstalk results from a novel mechanism of competition between stabilized Raf dimers and p110α for recruitment to Ras nanoclusters. CONCLUSIONS Our findings reveal that BRaf inhibitors disrupt Ras nanocluster dynamics with significant, yet divergent, consequences for MAPK and PI3K signaling.
Collapse
Affiliation(s)
- Kwang-jin Cho
- Department of Integrative Biology and Pharmacology, The University of Texas Medical School-Houston, 6431 Fannin Street, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L, Struss B, Gibney M, Armstrong RC, Gunawardane RN, Nepomuceno RR, Valenta I, Hua H, Gardner MF, Cramer MD, Gitnick D, Insko DE, Apuy JL, Jones-Bolin S, Ghose AK, Herbertz T, Ator MA, Dorsey BD, Ruggeri B, Williams M, Bhagwat S, James J, Holladay MW. Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E. J Med Chem 2012; 55:1082-105. [DOI: 10.1021/jm2009925] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Martin W. Rowbottom
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Raffaella Faraoni
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Qi Chao
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Brian T. Campbell
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Andiliy G. Lai
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Eduardo Setti
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Maiko Ezawa
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Kelly G. Sprankle
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Sunny Abraham
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Lan Tran
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Brian Struss
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Michael Gibney
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Robert C. Armstrong
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Ruwanthi N. Gunawardane
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Ronald R. Nepomuceno
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Ianina Valenta
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Helen Hua
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Michael F. Gardner
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Merryl D. Cramer
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Dana Gitnick
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Darren E. Insko
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Julius L. Apuy
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Susan Jones-Bolin
- Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States
| | - Arup K. Ghose
- Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States
| | - Torsten Herbertz
- Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States
| | - Mark A. Ator
- Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States
| | - Bruce D. Dorsey
- Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States
| | - Bruce Ruggeri
- Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States
| | - Michael Williams
- Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania
19380, United
States
| | - Shripad Bhagwat
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Joyce James
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| | - Mark W. Holladay
- Ambit Biosciences, 4215 Sorrento Valley
Boulevard, San Diego, California 92121, United
States
| |
Collapse
|
14
|
Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ. Small molecule inhibitors of BRAF in clinical trials. Bioorg Med Chem Lett 2012; 22:789-92. [PMID: 22222036 DOI: 10.1016/j.bmcl.2011.11.060] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Revised: 11/09/2011] [Accepted: 11/10/2011] [Indexed: 01/07/2023]
Abstract
Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.
Collapse
Affiliation(s)
- Alfonso Zambon
- The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
| | | | | | | | | |
Collapse
|
15
|
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 2011; 13:669-77. [PMID: 21884820 DOI: 10.1016/j.jmoldx.2011.07.002] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2011] [Revised: 06/30/2011] [Accepted: 07/06/2011] [Indexed: 01/15/2023] Open
Abstract
Alterations of BRAF are the most common known genetic aberrations in pediatric gliomas. They frequently are found in pilocytic astrocytomas, where genomic duplications involving BRAF and the poorly characterized gene KIAA1549 create fusion proteins with constitutive B-Raf kinase activity. BRAF V600E point mutations are less common and generally occur in nonpilocytic tumors. The development of BRAF inhibitors as drugs has created an urgent need for robust clinical assays to identify activating lesions in BRAF. KIAA1549-BRAF fusion transcripts have been detected in frozen tissue, however, methods for FFPE tissue have not been reported. We developed a panel of FFPE-compatible quantitative RT-PCR assays for the most common KIAA1549-BRAF fusion transcripts. Application of these assays to a collection of 51 low-grade pediatric gliomas showed 97% sensitivity and 91% specificity compared with fluorescence in situ hybridization or array comparative genomic hybridization. In parallel, we assayed samples for the presence of the BRAF V600E mutation by PCR pyrosequencing. The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively. These results show that fusion transcripts and mutations can be detected reliably in standard FFPE specimens and may be useful for incorporation into future studies of pediatric gliomas in basic science or clinical trials.
Collapse
|